Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H16N4O2.2ClH |
| Molecular Weight | 381.256 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CN1N(C(=O)C(NC(=O)C2=CC=CN=C2)=C1C)C3=CC=CC=C3
InChI
InChIKey=KOJCCAVPCPSQAR-UHFFFAOYSA-N
InChI=1S/C17H16N4O2.2ClH/c1-12-15(19-16(22)13-7-6-10-18-11-13)17(23)21(20(12)2)14-8-4-3-5-9-14;;/h3-11H,1-2H3,(H,19,22);2*1H
| Molecular Formula | C17H16N4O2 |
| Molecular Weight | 308.3345 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14133613Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/24954054
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14133613
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/24954054
Nifenazone is a drug that has been used as an analgesic for a number of rheumatic conditions. Later it was shown that nifenazone is not of significant value in the therapy of the chronic rheumatic disorders and that side-effects may be expected to occur, particularly in those patients who give a history of abnormal reactions to phenylbutazone and oxyphenbutazone.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The solvatochromic, spectral, and geometrical properties of nifenazone: a DFT/TD-DFT and experimental study. | 2014-08-07 |
|
| Evaluation of liver function during administration of nifenazone in rheumatic disease on the basis of serum protein studies and enzyme tests. | 1972-04-01 |
|
| TRIAL OF NIFENAZONE ("THYLIN"). | 1964-06-13 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14133613
750 - 2,000 mg. daily, orally in divided dosage.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:03:46 GMT 2025
by
admin
on
Mon Mar 31 22:03:46 GMT 2025
|
| Record UNII |
AJ9RXT13PC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51658-08-3
Created by
admin on Mon Mar 31 22:03:46 GMT 2025 , Edited by admin on Mon Mar 31 22:03:46 GMT 2025
|
PRIMARY | |||
|
71587162
Created by
admin on Mon Mar 31 22:03:46 GMT 2025 , Edited by admin on Mon Mar 31 22:03:46 GMT 2025
|
PRIMARY | |||
|
AJ9RXT13PC
Created by
admin on Mon Mar 31 22:03:46 GMT 2025 , Edited by admin on Mon Mar 31 22:03:46 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |